ClinicalTrials.gg
CompletedNCT03015532Updated Mar 2, 2026Results posted

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

A Phase 2 interventional study of HTX-011 and Saline Placebo in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Heron Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
16th of 364
285 · median 70
Started
2017
with 30 others
Phase 2
43 of 364
4 open now
Registered
103rd of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 16th largest by enrollment, is one of 31 that started in 2017, is one of 43 in phase 2, and was the 103rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgical site.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • knee
  • knee replacement
  • arthroplasty
  • joint replacement
  • knee pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo primary unilateral TKA under general anesthesia.
  • Has not previously undergone TKA in either knee.
  • Has an Physical Status of I, II, or III.
  • Is able to demonstrate motor function by performing a timed 20-meter walk unassisted, but with the optional use of a 4-legged walker for balance.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Has a planned concurrent surgical procedure (eg, bilateral TKA).
  • Has a pre-existing concurrent acute or chronic painful/restrictive physical condition that may require analgesic treatment in the postoperative period for pain.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
  • Has taken NSAIDs within 10 days prior to the scheduled surgery.
  • Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
  • Has been administered systemic within 5 half-lives or 10 days prior to administration of study drug.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • Has a known history of , (HIV), or active .
  • Has uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with study assessments.
  • Has any chronic neuromuscular deficit of either femoral nerve function or thigh musculature. Has any chronic condition or disease that would compromise neurological or vascular assessments.
  • Had a in the last year, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half lives.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a (BMI) >38 kg/m2.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Cohort 1, Group 1: HTX-011

    HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation

    Drug: HTX-011

  • Experimental
    Cohort 1, Group 2: HTX-011

    HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)

    Drug: HTX-011

  • Placebo comparator
    Cohort 1, Group 3: Saline Placebo

    Saline placebo via injection

    Drug: Saline Placebo

  • Active comparator
    Cohort 1, Group 4: Bupivacaine HCI

    Bupivacaine HCl without epinephrine, 125 mg via injection

    Drug: Bupivicaine HCl

  • Experimental
    Cohort 2, Group 1: HTX-011

    HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation

    Drug: HTX-011

  • Experimental
    Cohort 2, Group 2: HTX-011 + Ropivacaine

    HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection

    Drug: HTX-011 · Drug: Ropivacaine

  • Placebo comparator
    Cohort 2, Group 3: Saline Placebo

    Saline placebo via injection

    Drug: Saline Placebo

  • Active comparator
    Cohort 2, Group 4: Bupivacaine HCI

    Bupivacaine HCl without epinephrine, 125 mg via injection

    Drug: Bupivicaine HCl

Interventions

  • DrugHTX-011

    Drug pages: Bupivacaine · Meloxicam

    HTX-011 (bupivacaine/meloxicam), via instillation

  • DrugSaline Placebo

    Saline placebo via injection

  • Bupivacaine HCl without epinephrine

  • Ropivacaine, via injection

06

What researchers measure

Primary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).

    Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.

    Time frame: 48 hours

Secondary outcomes

  1. Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72).

    Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720.

    Time frame: 72 hours

  2. Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)

    Time frame: 72 hours

07

Results

Posted Oct 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
Started2022111058565355
Completed2022111058545155
Not completed00000220
Withdrew: Adverse event00000210
Withdrew: Withdrawal by subject00000010

Outcome measures

PrimaryMean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).

Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.

Time frame:
48 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).
pain intensity score*hrCohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).386.12 ± 82.930391.56 ± 84.450405.82 ± 97.549347.56 ± 103.422322.08 ± 99.669307.25 ± 127.674396.36 ± 77.468352.74 ± 100.887
SecondaryMean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72).

Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720.

Time frame:
72 hours
Reported as:
Mean · pain intensity score*hr
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72).
pain intensity score*hrCohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72).543.14 ± 142.566560.85 ± 136.099576.44 ± 150.815468.58 ± 179.687471.19 ± 149.443452.54 ± 194.095577.93 ± 125.102516.93 ± 152.512
SecondaryMean Total Postoperative Opioid Consumption (in Morphine Equivalents)
Time frame:
72 hours
Reported as:
Mean · morphine milligram equivalent (MME)
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)
morphine milligram equivalent (MME)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)65.53 ± 31.61566.86 ± 31.15470.41 ± 18.05760.70 ± 29.90364.39 ± 27.88960.32 ± 34.94973.55 ± 34.44868.35 ± 29.169

Adverse events

Collected over 28 Days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1, Group 1: HTX-0110/20 (0%)0/20 (0%)19/20 (95%)
Cohort 1, Group 2: HTX-0110/22 (0%)2/22 (9.1%)22/22 (100%)
Cohort 1, Group 3: Saline Placebo0/11 (0%)0/11 (0%)11/11 (100%)
Cohort 1, Group 4: Bupivacaine HCI0/10 (0%)1/10 (10%)10/10 (100%)
Cohort 2, Group 1: HTX-0110/58 (0%)1/58 (1.7%)55/58 (94.8%)
Cohort 2, Group 2: HTX-011 + Ropivacaine0/56 (0%)4/56 (7.1%)50/56 (89.3%)
Cohort 2, Group 3: Saline Placebo0/53 (0%)3/53 (5.7%)50/53 (94.3%)
Cohort 2, Group 4: Bupivacaine HCI0/55 (0%)2/55 (3.6%)49/55 (89.1%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventCohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
SyncopeNervous system disorders0/200/220/111/100/580/560/530/55
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/201/220/110/101/581/560/531/55
Post procedural haematomaInjury, poisoning and procedural complications0/201/220/110/100/580/560/530/55
HyponatraemiaMetabolism and nutrition disorders0/200/220/110/100/580/561/530/55
Cholecystitis acuteHepatobiliary disorders0/200/220/110/100/580/561/530/55
HaematomaVascular disorders0/200/220/110/100/580/561/530/55
HypoxiaRespiratory, thoracic and mediastinal disorders0/200/220/110/100/580/560/531/55
Urinary retentionRenal and urinary disorders0/200/220/110/100/581/560/530/55
Respiratory failureRespiratory, thoracic and mediastinal disorders0/200/220/110/100/581/560/530/55
Post procedural cellulitisInfections and infestations0/200/220/110/100/581/560/530/55
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCI
NauseaGastrointestinal disorders14/2016/226/114/1029/5830/5625/5330/55
ConstipationGastrointestinal disorders8/2010/222/113/1014/5821/5612/5318/55
HypertensionVascular disorders2/203/221/114/1011/588/568/537/55
DizzinessNervous system disorders5/205/224/113/109/588/569/538/55
VomitingGastrointestinal disorders7/206/224/112/1015/5814/5610/5315/55
HypokalaemiaMetabolism and nutrition disorders2/201/223/111/103/586/564/536/55
LeukocytosisBlood and lymphatic system disorders1/205/222/111/104/586/560/531/55
PyrexiaGeneral disorders1/205/220/112/108/588/562/538/55
TachycardiaCardiac disorders4/204/221/110/109/589/5611/536/55
HyperglycaemiaMetabolism and nutrition disorders0/200/220/112/101/582/560/530/55

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
<=18 years000000000
Between 18 and 65 years12175431343638177
>=65 years856627221717108
Age, Continuous
Age, Continuous(years)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
Mean62.1 ± 7.5258.6 ± 7.4464.9 ± 4.6465.3 ± 11.6262.5 ± 8.6363.2 ± 9.3661.5 ± 8.3161.4 ± 9.3762.1 ± 8.71
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
Female1397526272535147
Male7134532292820138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
Hispanic or Latino71031916121674
Not Hispanic or Latino13128949404139211
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
American Indian or Alaska Native010011003
Asian000001012
Native Hawaiian or Other Pacific Islander000000000
Black or African American5323658739
White15189751494547241
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1, Group 1: HTX-011Cohort 1, Group 2: HTX-011Cohort 1, Group 3: Saline PlaceboCohort 1, Group 4: Bupivacaine HCICohort 2, Group 1: HTX-011Cohort 2, Group 2: HTX-011 + RopivacaineCohort 2, Group 3: Saline PlaceboCohort 2, Group 4: Bupivacaine HCITotal
United States2022111058565355285
08

Study locations

24 sites
  • Mobile, Alabama 36608, United States
  • Sheffield, Alabama 35660, United States
  • Phoenix, Arizona 85015, United States
  • Phoenix, Arizona 85023, United States
  • La Jolla, California 92037, United States
  • Riverside, California 92503, United States
  • San Diego, California 92103, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33143, United States
  • Miami, Florida 33155, United States
  • Tamarac, Florida 33321, United States
  • Las Vegas, Nevada 89109, United States
  • Columbus, Ohio 43203, United States
  • Columbus, Ohio 43210, United States
  • Dayton, Ohio 45417, United States
  • Bellaire, Texas 77401, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77027, United States
  • Houston, Texas 77043, United States
  • Plano, Texas 75093, United States
  • San Antonio, Texas 78209, United States
  • San Antonio, Texas 78229, United States
  • San Antonio, Texas 78240, United States
  • Webster, Texas 77598, United States
09

References and documents

Publications

  • Lachiewicz PF, Lee GC, Pollak RA, Leiman DG, Hu J, Sah AP. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial. J Arthroplasty. 2020 Oct;35(10):2843-2851. doi: 10.1016/j.arth.2020.05.044. Epub 2020 May 27. PubMed 32561266 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2018, 15 months.

Results were first posted in Oct 2021, 3 years 6 months after primary completion. A results delay was requested in Jun 2018.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 15 months is above that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2017
First posted
Jan 10, 2017
StartActual
Jan 13, 2017
Primary completionActual
Apr 20, 2018
CompletionActual
May 16, 2018
Results delay requested
Jun 8, 2018
Results first posted
Oct 27, 2021
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03015532
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Jan 13, 2017
Primary completion
Apr 20, 2018
Completion
May 16, 2018
Results posted
Oct 27, 2021
Last update
Mar 2, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Meloxicam

Start the discussion